Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors

Medicine, Respiratory System, Oncology, Life Sciences, Biochemistry, Genetics,
MET   kinase domain   point mutation   lung cancer   malignancies   targeted therapy  

This study reveals a new targetable cancer subtype characterized by activating point mutations in the MET tyrosine kinase domain (TKD). Researchers identified MET TKD activating mutations in approximately 0.5% of patients across a genomic data set of over 600,000 cancer cases, encompassing various tumor types, with the highest prevalence in renal c...